Apigenin for Anxiety
Pure apigenin has no human trials for anxiety, so any benefit is inferred only from standardized chamomile extract, where a few small studies show modest, unreliable effects. Treat it as a possible mild aid at best, not a proven anxiety treatment.
Why this grade7-layer evidence engine
The grade is Weak because the human evidence does not actually test isolated apigenin. Every anxiety trial used whole chamomile extract standardized to ~1.2% apigenin, which contains many other bioactives, so any benefit cannot be pinned on apigenin alone. For the purified compound itself, only rodent and in-vitro GABA-A receptor data exist (PMID 10751547), with zero human RCTs.
Using chamomile as a proxy, the signal is genuine but thin. A small 8-week double-blind RCT in mild-to-moderate generalized anxiety found a significant symptom reduction (PMID 19593179, n=57, p=0.047), and an exploratory analysis suggested mood benefits (PMID 22894890). However, the 38-week long-term trial missed its primary relapse-prevention endpoint (PMID 27912875, n=179, p=0.16), and both anchor trials came from a single research group, limiting independent confirmation.
Authorities reinforce this caution rather than endorsement. NIH/NCCIH states there is not enough evidence to conclude chamomile helps any condition, with only limited support from small studies. Mayo Clinic, Cleveland Clinic, Harvard Health, and the ADAA do not endorse apigenin and flag a bleeding-risk interaction with blood thinners; apigenin also inhibits CYP2C9/CYP3A4 in vitro, so high doses may affect some medications.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.505
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status